Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
from Sanofi - Aventis Groupe https://ift.tt/WlwxfI3
via IFTTT
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
https://ift.tt/CQreAx9
from Sanofi - Aventis Groupe https://ift.tt/WlwxfI3
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/WlwxfI3
via IFTTT
Tags:
Posted by: Nitesh sinha
You may like these posts
health-issuePress Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
- health-issue
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
- health-issue
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
0 Comments
Please ,
Do not enter any kind of span link